

International Medical Advisory Board (IMAB) Members

Jacques Galipeau, M.D., FRCP(C) – Chair	Director of the University of Wisconsin advanced cell therapy program, Assistant dean for therapeutics discovery and development at the University of Wisconsin School of Medicine and Public Health.
Catherine M. Bollard, MBChB, M.D., FRACP, FRCPA	Chief, Division Allergy and Immunology, Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine Director.
Daniel Weiss, M.D., Ph.D.	Professor of Medicine, Pulmonary Medicine, University of Vermont.
Dixon Kaufman, M.D., Ph.D.	Director, Transplant Service Line of the University of Wisconsin Hospitals and Clinic, Surgical Director of the Kidney Transplant Program.
Donald G. Stein, Ph.D.	Asa G. Candler Professor and Distinguished Professor in Emergency Medicine at Emory University School of Medicine (Atlanta, GA)
John Rasko, Ph.D., MAICD, RCPA, FRCPA, FRACP, FAHMS	Director of the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital, Head of the Gene and Stem Cell Therapy Program at the Centenary Institute. (Sydney, AU)
Katarina Le Blanc, M.D., Ph.D.	Professor of Clinical Stem Cell Research at the Karolinska Institutet.
Massimo Dominici, M.D.	Assistant professor in Oncology and Hematology at the University of Modena and Reggio Emilia, Chair of the ISCT advisory board

Jacques Galipeau, M.D., FRCP(C) – Chair



Dr. Galipeau is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison. He obtained his Medical Degree from the University of Montreal in 1988 and completed specialty training in internal medicine at the McGill-affiliated Jewish General Hospital. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology and Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children's research hospital in Memphis Tennessee. In his 12-year career at McGill University

starting in 1997, he initiated and developed a research program in mesenchymal stromal cells (MSCs), cell and immunotherapy of catastrophic illnesses including cancer and immune disease. He relocated to Emory University in October 2009 where he established the Emory Personalized Immunotherapy Center [EPIC] whose mission was to develop evidence-based and innovative personalized cell therapies for immune and malignant disorders. He is an internationally recognized expert in translational development of MSC cell therapies and the sponsor of a series of FDA INDs examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders. As of September 1st, 2016, Dr. Galipeau is the inaugural director of the University of Wisconsin advanced cell therapy program and assistant dean for therapeutics discovery and development at the University of Wisconsin School of Medicine and Public Health.

Catherine Bollard, MBChB, MD, FRACP, FRCPA



Catherine Bollard worked both in New Zealand and London, England before moving to Baylor College of Medicine (BCM) in 2000 where she was Professor of Pediatrics, Medicine and Immunology and the Director of the Texas Children's Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she moved to Children's National and The George Washington University School of Medicine and Health Sciences in Washington, DC. She is currently Chief, Division of Allergy and Immunology, Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine and Director of the Program for Cell Enhancement and Technologies for

Immunotherapy (CETI). She is a member of the American Society for Clinical Investigation (ASCI) and is President of the International Society for Cellular Therapy (ISCT). She is on the Board of Directors of the Foundation for the Accreditation of Cellular Therapy (FACT) and Chairs the Non Hodgkin's Lymphoma committee of the Children's Oncology Group. She is an Associate Editor for the journals *Blood* and *Cytotherapy* and is a member of the NCI Clinical Oncology Study Section and is a member of the Cellular, Tissues and Gene Therapies Advisory Committee for the Food and Drug Administration (FDA).

Daniel Weiss, M.D., Ph.D.



Dr. Weiss is professor of Medicine at the University of Vermont and has had a longstanding interest in lung repair and regeneration after injury, notably gene and cell therapy approaches for lung diseases. In particular this has included developing novel techniques with which to investigate and enhance lung gene and cell therapies. Recent published work in cell therapy approaches for lung diseases has included several benchmark publications that have included the first ever trial of cell therapy for COPD and that have helped define whether exogenous cells can engraft in the lung. As such, Dr. Weiss is a translational scientist whose work spans from bench top to clinical trials. He has also instituted a biennial

meeting held at the University of Vermont, Stem Cells and Cell Therapies in Lung Biology and Diseases that is widely viewed by the NIH, FDA and non-profit Respiratory Disease Foundations as the major meeting in the field. Dr. Weiss' overall goal is to provide a firm scientific basis for clinical application of cell therapies in lung diseases. He has been funded by the NIH, DOD, non-profit Respiratory Disease Foundations, and by industry sources since 1995.

Dixon B. Kaufman, M.D., Ph.D.




Dixon B. Kaufman is the Ray D. Owen Professor and Chair of the Division of Transplantation of the Department of Surgery at the School of Medicine and Public Health of the University of Wisconsin - Madison. He is also the Transplant Service Line Director of the University of Wisconsin Hospitals and Clinic, and the surgical director of the Kidney Transplant Program.

His clinical focus has been on kidney, pancreas and islet transplantation. His basic research efforts have focused on the immunobiology of islet transplantation, and most recently, kidney transplant immunological tolerance induction, both supported by the NIH Non-human Primate

Consortium Study Group. His clinical research includes the National Institutes of Health (NIH)-supported Clinical Islet Transplant (CIT) consortium. His CV lists over 200 manuscripts and book chapters. Dr. Kaufman has held national leadership positions in many facets of the transplant field. He is currently Secretary of the American Society of Transplant Surgeons. Dr. Kaufman is also active with the United Network for Organ Sharing. Dr. Kaufman is an associate editor for the American Journal of Transplantation, Transplantation Journal, and Clinical Transplantation Journal.

Donald G. Stein, Ph.D.



Donald G. Stein, Ph.D., is Asa G. Candler Professor and Distinguished Professor in Emergency Medicine at the Emory University School of Medicine in Atlanta, Georgia. Dr. Stein served Emory as Vice Provost for Graduate Studies, Dean of the Graduate School of Arts and Sciences and interim Vice President for Research. Stein was also Vice Provost for Research and Dean of the Graduate School at Rutgers University, Newark, and adjunct professor of Neurology at the University of Medicine and Dentistry of New Jersey.

His laboratory focuses on recovery of function after stroke and traumatic injury to the brain. He was one of the first to demonstrate sex differences in the outcome of brain injury, findings which led to decades of research on neurosteroid actions in brain repair. Stein is the author of hundreds of papers, book chapters, and reviews on recovery from brain injury, and has authored or edited more than a dozen books on the topic, and lectured nationally and internationally. He has won numerous awards and fellowships for his contributions to the field of neuroplasticity and brain repair.

John Rasko, PhD, MAICD, RCPA, FRCPA, FRACP, FAHMS



Professor Rasko directs the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital and heads the Gene and Stem Cell Therapy Program at the Centenary Institute, University of Sydney. He serves on Hospital, state and national bodies including Chair of GTTAC, Office of the Gene Technology Regulator – responsible for regulating all genetically-modified organisms in Australia - and immediate past Chair of the Advisory Committee on Biologicals, Therapeutic Goods Administration. Contributions to scientific organisations include co-founding (2000) and past-President (2003-5) of the Australasian Gene Therapy Society; Vice President (2008-12)

and President-Elect (2016-17) International Society for Cellular Therapy; Scientific Advisory Committees and Board member for philanthropic foundations; and several Human Research Ethics Committees. He is a founding Fellow of the Australian Academy of Health and Medical Sciences. He is the recipient of national (RCPA, RACP, ASBMB) and international awards in recognition of his commitment to excellence in medical research, including appointment as an Officer of the Order of Australia.

Katarina Le Blanc, M.D., Ph.D.



Katarina Le Blanc received her M.D. from the Karolinska Institutet in 1993, and her Ph.D. in 1999, also from the Karolinska Institutet. In 2002 she became a certified specialist in hematology. Dr. Le Blanc's main research interest is mesenchymal stem cells, haematopoietic stem cell transplantation and immunology. Dr. Le Blanc is a member of several international and national committees including notably the Nobel Assembly at Karolinska Institutet and The Royal Swedish Academy of Science. She is also the member of several advisory boards and has been responsible for the organization of several national and international scientific

meetings, and also served on many program committees. She has mentored many trainees, PhD students and post docs over the years. Katarina has published well over 100 peer-reviewed publications and review articles, been cited more than 12.000 times, and given some 140 presentations at various national and international meetings over the last 10 years. She is the recipient of several awards including the Knut & Alice Wallenberg Foundation award for young female researchers, Swedish Medical Society award for young scientists, and the Tobias Foundation Prize for the excellent studies of the immunological properties of mesenchymal stem cells and their use in mesenchymal stem cell therapy awarded by the Royal Swedish Academy of Science.

Massimo Dominici, M.D.



Massimo Dominici is a clinical scientist developing cell and gene therapy approaches around cancer patients. He got his M.D. degree at the University of Pavia (Italy) then internship, residency and post-doctoral training between the Institute of Haematology, Vienna University (Austria), the Division of Immuno-haematology, Ferrara University (Italy) and St Jude Children's Hospital, Memphis (USA). Then a hospital physician, Massimo was an Associate Professor of Medical Oncology, Head of the Laboratory of Cellular Therapies, and Director of the residency school in medical oncology at the University of Modena and Reggio Emilia (Modena, Italy). Dominici, has more than 110 papers published or in press on stem cells, tissue regeneration, experimental oncology and hematology with over 12 500 citations, H-index: 32. Author of 3 books, 3 chapters and 7 patents, Dr. Dominici is the scientific founder of the University start-up Rigenrand. He is also the founder and scientific coordinator of the Mirandola Science & Tecnology Park. Co-editor, editorial board member and referee for over 50 scientific Journals. Referee for 16 national & international founding Bodies. He has been co-founder of the Forum of Italian Researcher on MSC (FIRST), board member of JACIE, WBMT and advisor for the Italian Minister of Health. He has been member of ISCT, ASH, ESCGT, IFATS, IPLASS. He has been President of ISCT 2014-2016, now Chair of the ISCT advisory board and chair of the ISCT presidential task force on unproven cellular therapy.